Bayer CropScience

Chemicals

BAYERCROP NSE

NSE: BAYERCROP BSE: 506285 Pesticides & Agrochemicals

₹3,249.90 −29.50 (−0.90%)

P/E: 19.95

View as Markdown

MCP

Close 4 Nov 2026 ₹3,249.90 −1,494.80 −31.5% 1Y

Start ₹4,744.70

Key Fundamentals

SmallcapFertilizers & AgrochemicalsChemicals

Price-based figures as of 04 Nov 2026, 15:54 IST · EPS basis: Standalone · TTM

ROCE: 29.10%
Debt to Equity: 0.03
EPS (TTM): ₹162.90
Book Value: ₹659.90

Market Cap: —
P/E (TTM): 19.95
P/B: 4.92
ROE: 23.70%
Dividend Yield: 4.57%
EBITDA: ₹969 Cr
52W High: ₹5,063.00
52W Low: ₹3,226.10
Day Range: ₹3,226.10 – ₹3,280.00
Volume: 85,948

Peer Comparison

Commodities › Chemicals › Pesticides & Agrochemicals

Bayer CropScience peer comparison

UPL	₹529.00	22.09	₹43,728 Cr	1.28	1.16%	5.64%	10.10%	₹52,804 Cr	₹2,323 Cr
PI Industries	₹2,187.00	28.48	₹33,248 Cr	2.95	0.69%	11.20%	15.00%	₹6,516 Cr	₹1,164 Cr
Sumitomo Chemical	₹328.10	28.24	₹15,980 Cr	4.43	0.41%	17.60%	23.50%	₹3,192 Cr	₹581 Cr
Bayer CropScience (this company)	₹3,249.90	19.95	₹14,602 Cr	4.92	4.57%	23.70%	29.10%	₹5,595 Cr	₹733 Cr
Sharda Cropchem	₹677.95	9.77	₹6,015 Cr	1.88	2.23%	23.20%	30.20%	₹5,357 Cr	₹626 Cr
Dhanuka Agritech	₹942.75	15.83	₹4,217 Cr	2.50	0.21%	18.50%	23.80%	₹1,953 Cr	₹268 Cr
Rallis	₹189.67	17.23	₹3,734 Cr	1.68	1.58%	10.20%	14.10%	₹2,962 Cr	₹214 Cr
Median 7 companies	₹677.95	19.95	₹14,602 Cr	2.50	1.16%	17.60%	23.50%	₹5,357 Cr	₹626 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of 4 Nov 2026. How it works →

Overall score

53 Average

Data confidence 100/100

Category scores

Quality: 82; Strong; Returns, margins, earnings quality 22% weight
Valuation: 62; Good; Cheap vs sector & own history 24% weight
Growth: 13; Poor; Sales & profit trajectory 9% weight
Financial Health: 78; Strong; Solvency, leverage, coverage 9% weight
Momentum: 10; Poor; Trend strength, vol-adjusted 12% weight
Ownership: 47; Average; FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

Company has reduced debt.
Company is almost debt free.
Stock is providing a good dividend yield of 4.27%.
Company has been maintaining a healthy dividend payout of 93.8%
Company's working capital requirements have reduced from 74.0 days to 56.1 days

Weaknesses

The company has delivered a poor sales growth of 5.90% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
Group	Signal	Bearish	Neutral	Bullish
Overall	Strong Bearish	12	2	5
Oscillators	Strong Bullish	2	2	5
Moving Averages	Strong Bearish	10	0	0

Oscillators

Strong Bullish

Bearish

Neutral

Bullish

Overall

Strong Bearish

Bearish

Neutral

Bullish

Moving Averages

Strong Bearish

Bearish

Neutral

Bullish

Key readings

RSI (14): 28.34; Bullish
MACD (12,26,9): −123.74; Bearish
SMA (50): 3,685.15; Bearish
SMA (200): 4,249.76; Bearish

As of 4 Nov 2026

Analyst Rating

Based on 7 analysts

4 of 7 analysts rate Buy, 3 Hold, 0 Sell.

As of 4 Nov 2026

BUY

57%

HOLD

43%

SELL

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y	+7.44%
5Y	+5.90%
3Y	+3.36%
1Y	+3.69%
TTM	−2.80%

Net profit

Net profit growth by window
10Y	+8.14%
5Y	+6.92%
3Y	−3.13%
1Y	+21.30%
TTM	+23.82%

Operating cash flow

Operating cash flow growth by window
10Y	+18.00%
5Y	+9.43%
3Y	+20.97%
1Y	+311.45%
TTM	—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y	−0.31 pp
5Y	−3.66 pp
3Y	−2.58 pp
1Y	+2.77 pp
TTM	+3.40 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017	₹2,803 Cr
Mar 2018	₹2,710 Cr
Mar 2019	₹3,167 Cr
Mar 2020	₹3,609 Cr
Mar 2021	₹4,261 Cr
Mar 2022	₹4,734 Cr
Mar 2023	₹5,140 Cr
Mar 2024	₹5,106 Cr
Mar 2025	₹5,473 Cr
Mar 2026	₹5,675 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017	₹291 Cr
Mar 2018	₹300 Cr
Mar 2019	₹337 Cr
Mar 2020	₹474 Cr
Mar 2021	₹493 Cr
Mar 2022	₹645 Cr
Mar 2023	₹758 Cr
Mar 2024	₹740 Cr
Mar 2025	₹568 Cr
Mar 2026	₹689 Cr

Analyst Forecasts

Forecast For

FY27 consensus · EBITDA

₹968 Cr −0.1% vs FY26

Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026

AI opinion · based on fundamentals

Risk medium

Bayer CropScience Ltd trades at ₹3,249.9 as of 2026-11-04 with a market cap of ₹14,601.69 crore, a PE of 19.95x, and an ROCE of 27.93%. The stock sits near its 52-week low of ₹3,226.1 after a 30% decline over the past year, while the company remains virtually debt-free with a debt-to-equity of 0.03 and offers a dividend yield of 4.57%.

Bull Case 7

The company is virtually debt-free with a debt-to-equity ratio of just 0.03, providing significant financial flexibility and resilience against interest rate cycles.
ROE of 23.24% and ROCE of 27.93% as of 2026-11-04 indicate strong capital efficiency, with a 5-year average ROE of 24% demonstrating consistency in generating shareholder returns.
Dividend yield of 4.57% is attractive for an agrochemicals company, supported by a healthy dividend payout ratio of 93.8%, signalling management confidence in cash flow stability.
TTM profit growth of 24% marks a sharp acceleration compared to the 3-year compounded profit growth of just 1%, suggesting a potential earnings inflection.
Working capital days have improved from 74.0 days to 56.1 days, reflecting better inventory and receivables management and freeing up cash for operations.
10-year compounded profit growth of 8% and 10-year ROE averaging 21% demonstrate a track record of long-term value creation through business cycles.
The price-to-book ratio of 4.92x, while not cheap in absolute terms, is reasonable given an ROCE of 27.93% and near-zero leverage, reflecting genuine asset-light value creation.

Bear Case 8

The stock has declined 30% over the past 1 year and shows a negative 10-year stock CAGR of -2%, indicating persistent long-term value erosion for shareholders despite operational profitability.
TTM sales growth is negative at -3%, and 3-year compounded sales growth is only 3%, pointing to revenue stagnation that may limit future earnings expansion.
5-year compounded sales growth of just 6% and a noted poor sales growth of 5.90% over the past five years suggest the company is struggling to grow its top line meaningfully.
The 3-year stock CAGR of -13% and 5-year stock CAGR of -8% show sustained market de-rating, indicating the market has been unwilling to reward earnings with higher multiples.
A dividend payout ratio of 93.8% leaves very little room for reinvestment in the business, which could constrain future growth and limit the company's ability to fund expansion organically.
3-year compounded profit growth of only 1% suggests the recent TTM profit jump of 24% may be lumpy or non-recurring rather than indicative of a durable trend.
The stock is trading near its 52-week low of ₹3,226.1, just 0.7% above that level, which may reflect ongoing negative market sentiment or structural concerns about growth.
As a subsidiary of a global parent, strategic decisions including product launches, R&D priorities and capital allocation may be dictated by the parent's global strategy rather than optimised for Indian market opportunities.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Bayer CropScience shows stable governance with a near-unanimous independent director appointment and orderly board transitions. No operational or financial headwinds surfaced in recent disclosures. The leadership changes are routine and tied to parent-company realignment rather than any red flags. Investors should watch for any strategic shifts once the new board composition takes effect in late 2026.

Positives 1

Director approved near-unanimously Oct 14

Shareholders approved Ravi Moti Kirpalani as Independent Director with 99.99% votes in favor, signaling strong governance confidence.

Neutral 1

Board reshuffle, new director named Nov 3

Dr. Thomas Hoffmann resigned effective Nov 30, 2026 due to expanded Bayer AG duties; Ms. Christiane Temminghoff appointed as Additional Director effective Dec 1, 2026. Rajaram Mohan Babu Boppana also resigned as Cluster Commercial Lead effective Dec 31, 2026 to pursue an external opportunity.

Quarterly Results

₹ Cr

BAYERCROP quarterly results, ₹ crore
Particulars	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,740	1,617	955	792	1,631	1,738	1,057	1,046	1,915	1,553	1,106	1,101	1,835
Expenses	1,315	1,312	827	695	1,317	1,554	1,037	876	1,566	1,348	989	898	1,467
Operating Profit	425	305	128	97	314	184	20	171	348	205	117	203	368
OPM %	24%	19%	13%	12%	19%	11%	1.9%	16%	18%	13%	11%	18%	20%
Other Income	21	16	15	29	27	24	32	37	19	14	16	47	89
Interest	8	4	3	5	4	3	4	6	5	4	5	6	4
Depreciation	31	12	15	16	22	14	15	34	27	14	15	38	50
PBT	406	306	124	105	316	190	34	168	335	200	113	206	402
Tax %	19%	27%	25%	9%	20%	28%	−2%	15%	17%	24%	15%	21%	20%
Net Profit	328	223	93	96	254	136	34	143	279	153	96	162	322
EPS (₹)	73.09	49.6	20.72	21.36	56.56	30.33	7.61	31.89	62.01	33.98	21.29	36.07	71.56

Profit & Loss

₹ Cr

BAYERCROP profit and loss, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	3,660	2,769	2,803	2,710	3,167	3,609	4,261	4,734	5,140	5,106	5,473	5,675	5,595
Expenses	3,144	2,334	2,389	2,300	2,684	2,883	3,450	3,923	4,216	4,147	4,783	4,801	4,702
Operating Profit	516	435	414	410	483	726	812	812	924	959	691	874	893
OPM %	14%	16%	15%	15%	15%	20%	19%	17%	18%	19%	13%	15%	16%
Other Income	88	82	70	39	51	−64	69	112	168	76	118	95	165
Interest	5	10	7	11	10	14	13	13	22	20	17	20	19
Depreciation	25	25	29	33	44	65	74	64	80	74	85	94	117
PBT	574	482	448	404	480	583	794	847	990	941	707	855	922
Tax %	33%	35%	35%	26%	30%	19%	38%	24%	23%	21%	20%	19%	—
Net Profit	383	315	291	300	337	474	493	645	758	740	568	689	732
EPS (₹)	105	89.13	82.31	87.41	98.18	106	110	144	169	165	126	153	163
Div. Payout %	20%	19%	21%	21%	18%	24%	105%	104%	77%	85%	99%	98%	—

Balance Sheet

₹ Cr

BAYERCROP balance sheet, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	37	35	35	34	34	45	45	45	45	45	45	45
Reserves	1,996	1,804	2,021	1,744	2,205	2,528	2,505	2,479	2,667	2,804	2,806	2,921
Borrowings	0	0	0	0	0	2	26	86	74	47	105	82
Other Liabilities	740	597	769	756	1,310	1,262	1,663	1,742	1,893	1,701	2,290	2,652
Total Liabilities	2,773	2,437	2,825	2,535	3,549	3,836	4,239	4,353	4,679	4,597	5,246	5,699
Fixed Assets	322	290	342	334	440	468	425	468	462	414	470	458
CWIP	1	17	24	36	47	56	76	98	109	119	119	127
Investments	29	68	50	0	0	41	52	38	41	54	35	57
Other Assets	2,422	2,062	2,410	2,164	3,062	3,270	3,686	3,749	4,066	4,010	4,622	5,056
Total Assets	2,773	2,437	2,825	2,535	3,549	3,836	4,239	4,353	4,679	4,597	5,246	5,699

Cash Flow

₹ Cr

BAYERCROP cash flow, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating	200	206	157	121	433	666	687	216	609	952	262	1,078
Investing	485	16	−8	38	−113	−29	7	64	83	0	86	72
Financing	−42	−590	−73	−581	−158	−148	−556	−703	−613	−656	−619	−624
Net Cash Flow	644	−367	76	−421	162	489	138	−424	79	296	−272	527
Free Cash Flow	297	170	108	80	378	638	656	168	537	912	222	1,014
CFO/OP	76	86	74	53	132	110	105	59	92	113	61	142

Ratios

BAYERCROP financial ratios, annual
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	57	53	72	89	81	73	65	77	69	69	63	72
Inventory Days	85	169	178	175	294	206	226	235	268	222	319	289
Days Payable	40	52	67	67	164	101	142	127	129	87	148	167
Cash Conversion Cycle	102	171	184	197	211	177	149	185	208	204	234	193
Working Capital Days	53	92	104	134	116	77	61	84	86	78	88	56
ROCE %	31%	25%	23%	22%	25%	30%	31%	31%	34%	34%	25%	29%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

62 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

Promoters 71.43%
DIIs 11.52%
Public 8.75%
Others 4.34%
FIIs 3.95%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Q2 FY26 concall · Nov 2025
Transcript PPT
Q1 FY25 concall · Aug 2024
Transcript PPT
Q4 FY23 concall · Jun 2023
Transcript PPT
Q4 FY22 concall · Jun 2022
Transcript PPT
Q2 FY22 concall · Nov 2021
Transcript PPT

Frequently Asked Questions about Bayer CropScience

What does Bayer CropScience Ltd do?

Bayer CropScience is engaged in Agri Care business which primarily includes manufacture, sale and distribution of insecticides, fungicides, herbicide and various other agrochemical products and corn seeds.

Where is Bayer CropScience Ltd (BAYERCROP) listed?

Bayer CropScience Ltd trades as BAYERCROP on the NSE and under code 506285 on the BSE.

Which sector does Bayer CropScience Ltd belong to?

Bayer CropScience Ltd is classified under the Chemicals sector, in the Pesticides & Agrochemicals industry.

What is the PE ratio of Bayer CropScience Ltd?

Bayer CropScience Ltd trades at a PE ratio of 19.95 as of 4 Nov 2026, on earnings per share of ₹162.9, against a book value of ₹659.9 per share.

What is the 52-week high and low of Bayer CropScience Ltd?

Over the last 52 weeks Bayer CropScience Ltd has traded between ₹3,226.1 and ₹5,063 as of 4 Nov 2026.

Does Bayer CropScience Ltd pay dividends?

Bayer CropScience Ltd has a dividend yield of 4.57%.

What is the Return on Equity (ROE) of Bayer CropScience Ltd?

Bayer CropScience Ltd reported a return on equity of 23.70%. Its debt-to-equity ratio is 0.03.

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BAYERCROP.md for Bayer CropScience Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Fertilizer & Agrochemical stocks → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List FII and DII flows, month by month How Tapetide Scores changed, month by month Stocks mutual funds are buying, month by month

Bayer CropScience

Key Fundamentals

Peer Comparison

Overall score

Category scores

Key Insights

Strengths

Weaknesses

Technical Indicators

Oscillators

Overall

Moving Averages

Key readings

Analyst Rating

Growth Rate

Revenue

Net profit

Operating cash flow

Operating margin· change in pp

Revenue by year

Net profit by year

Analyst Forecasts

AI Analysis — Bull vs Bear

AI News Digest

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Insights

Shareholding Pattern

Documents

Frequently Asked Questions about Bayer CropScience

Company Information

For AI agents and developers

Explore More